The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (2,388.04) USD. With the latest stock price at 9.18 USD, the upside of Immunitybio Inc based on DCF is -26113.5%.
Based on the latest price of 9.18 USD and our DCF valuation, Immunitybio Inc (IBRX) is a sell. selling IBRX stocks now will result in a potential gain of 26113.5%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.6% - 7.4% | 6.5% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (9,196.81) - (1,394.33) | (2,388.04) |
| Upside | -100283.1% - -15288.8% | -26113.5% |